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Summary  Heart  failure  constitutes  an  important  medical,  social  and  economic  problem.  The
prevalence  of  heart  failure  is  estimated  as  2—3%  of  the  adult  population  and  increases  with
age, despite  the  scientiﬁc  progress  of  the  past  decade,  especially  the  emergence  of  natriuretic
peptides,  which  have  been  widely  used  as  reliable  markers  for  diagnostic  and  prognostic  evalu-
ation. Identiﬁcation  of  new  reliable  markers  for  diagnosis,  analysis,  prognosis  of  mortality  and
prevention  of  hospitalization  is  still  necessary.  Galectin-3  is  a  soluble  -galactoside-binding  pro-
tein secreted  by  activated  macrophages.  Its  main  action  is  to  bind  to  and  activate  the  ﬁbroblasts
that form  collagen  and  scar  tissue,  leading  to  progressive  cardiac  ﬁbrosis.  Numerous  experimen-
tal studies  have  shown  the  important  role  of  galectin-3  in  cardiac  remodelling  due  to  ﬁbrosis,
independent  of  the  ﬁbrosis  aetiology.  Galectin-3  is  signiﬁcantly  increased  in  chronic  heart  fail-
ure (acute  or  non-acute  onset),  independent  of  aetiology.  Some  clinical  studies  have  conﬁrmed
the predictive  value  of  galectin-3  in  all-cause  mortality  in  patients  with  heart  failure.  In  our
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review,  we  aim  to  analyse  the  role  of  galectin-3  in  the  development  of  heart  failure,  its  value
in screening  and  clinical  decision  making  and  its  possible  predictive  application  in  follow-up  as
a ‘‘routine’’  test  in  an  addition  to  established  biomarkers,  such  as  B-type  natriuretic  peptide
and N-terminal  prohormone  of  B-type  natriuretic  peptide.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’insufﬁsance  cardiaque  reste  en  dépit  des  dernières  avancées  médicales  une
pathologie  fréquente,  grave  et  coûteuse.  De  ce  fait,  l’identiﬁcation  de  marqueurs  alternat-
ifs ou  complémentaires  au  dosage  des  peptides  natriurétiques  reste  un  élément  crucial  dans  la
prise en  charge  de  cette  pathologie  que  ce  soit  pour  le  diagnostic,  l’analyse  pronostique  ou  le
suivi des  patients.  La  galectine-3  est  une  protéine  sécrétée  par  les  macrophages  activés.  Son
action principale  est  de  se  lier  et  d’activer  les  ﬁbroblastes  qui  vont  sécréter  du  collagène  et
former ainsi  un  tissu  cicatriciel  qui  conduit  à  une  ﬁbrose  cardiaque  progressive.  De  nombreuses
études expérimentales  ont  mis  en  avant  le  rôle  clef  de  la  galectine-3  dans  le  remodelage  ﬁbro-
tique myocardique.  Cette  revue  des  données  actuellement  existantes  porte  sur  l’analyse  des
possibilités  offertes  par  le  dosage  de  ce  marqueur  sur  les  plans  diagnostique,  pronostique  et
éventuellement  en  tant  qu’outil  d’aide  au  monitoring  en  association  aux  marqueurs  actuelle-
ment recommandés  dans  l’insufﬁsance  cardiaque  aiguë  ou  chronique.
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tructural, biochemical and functional
haracteristics of galectin-3
alectins,  an  ancient  lectin  family,  are  characterized  by
peciﬁc  binding  of  -galactosides  through  evolutionary  con-
erved  sequence  elements  of  the  carbohydrate-recognition
omain.  A  structurally  unique  member  of  the  family  is
alectin-3;  in  addition  to  the  carbohydrate-recognition
omain,  it  contains  a  proline-  and  glycine-rich  N-terminal
omain  through  which  it  is  able  to  form  oligomers.  From  the
vailable  data,  galectin-3  is  expressed  in  various  tissues  and
ell  types,  and  is  detectable  inside  and  outside  cells  as  well
s  on  cell  surfaces.  The  biological  roles  of  galectin-3  were
nitially  attributed  to  its  carbohydrate-binding  activity,  but
uring  the  past  decade,  a  whole  new  spectrum  of  functions,
nrelated  to  lectin  activity,  has  been  revealed  [1].
Galectin-3  has  been  found  to  be  involved  in  many  bio-
ogical  processes,  such  as  cell-cell  and  cell-extracellular
atrix  adhesion,  cell  growth  and  differentiation,  the  cell
ycle,  signalling,  apoptosis  and  angiogenesis.  Consequently,
alectin-3  is  involved  in  the  regulation  of  development,
mmune  reactions,  tumourigenesis,  tumour  growth  and
etastasis  [1,2].
hysiopathology
ardiac  remodelling  is  one  of  the  main  components  of
hronic  heart  failure  (HF)  [3].  Adaptation  of  cardiomy-
cytes  is  critical  in  the  remodelling  process.  In  response  to
cute  and  chronic  damage,  the  immune  cells  recruit  to  the
yocardium,  with  the  production  of  cell-signalling  proteins
nd  the  activation  of  ﬁbroblasts  and  myoﬁbroblasts,  which
ead  to  the  deposition  of  procollagen  into  the  extracellular
atrix  and  cardiac  ﬁbrosis  [4].  This  part  of  the  pathophysi-
logical  pathway  is  difﬁcult  to  analyse  using  biomarkers  and
ven  by  magnetic  resonance  imaging.
t
H
P
as  droits  réservés.
The  up-regulation  of  myocardial  galectin-3  has  been
emonstrated  in  a rat  model  of  HF-prone  hyperten-
ive  hearts  [5],  interferon  6-induced  murine  chronic
ctive  myocarditis  and  cardiomyopathy,  rat  streptozotocin-
nduced  diabetic  cardiomyopathy  and  rat  angiotensin
I-induced  hypertension;  in  several  studies,  this  up-
egulation  was  associated  with  the  concomitant  activation
f  macrophages.  Galectin-3  has  also  been  found  to  be  signif-
cantly  up-regulated  in  the  hypertrophied  hearts  of  patients
ith  aortic  stenosis  and  in  the  plasma  of  patients  with  acute
nd  chronic  HF.  Galectin-3  may  be  involved  in  the  develop-
ent  of  HF.  It  is  speculated  that  blockade  of  galectin-3  may
low  the  progression  of  HF  and  possibly  reduce  HF-related
orbidity  and  mortality.  On  the  other  hand,  there  are  strong
rguments  that  connect  cardiac  remodelling  with  galectin-3
iology,  such  as  decreased  negative  change  in  the  pressure
ver  time  response  to  isoproterenol  challenge,  the  ratio  of
arly  left  ventricular  ﬁlling  phase  to  atrial  contraction  phase
nd  left  ventricular  ejection  fraction  (LVEF)  [6].
xperimental studies
harma  et  al.  [5]  showed  that  galectin-3  infusion  into  the
ericardium  of  normal  rats  led  to  the  development  of  car-
iac  remodelling.  The  highest  expression  level  of  galectin-3
rotein  was  observed  in  the  same  group  of  animals  that  had
he  highest  degree  of  cardiac  ﬁbrosis  and  had  developed
F  by  12—14  weeks  (densitometric  units:  HF  94.66—9.5;
ompensated  35—5.6;  controls,  27.2—6.2;  P  <  0.05  versus
ompensated  and  controls).  A  computer-assisted  densit-
metric  analysis  of  the  picrosirius  red-stained  sections
or  the  quantiﬁcation  of  myocardial  collagen  revealed
 higher  degree  of  interstitial  collagen  content  in  the
ailing  Ren-2  rats  compared  with  compensated  and  wild-
ype  rats  (interstitial  collagen  volume  fraction  percentage:
F  7.8—0.38;  compensated  3.8—0.54;  wild-type  2.5—0.3;
 <  0.05  versus  compensated  and  wild-type).  Liu  et  al.  [6]
lso  conﬁrmed  the  pathogenic  effects  of  intrapericardial
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aGalectin-3  
infusion  of  galectin-3  in  adult  male  rats.  Macrophages  (ED1-
positive  cells)  in  the  myocardium  increased  signiﬁcantly
in  the  galectin-3  treatment  group  compared  with  vehicle
(P  <  0.01).  There  was  also  a  signiﬁcant  increase  in  mast  cell
density  in  the  galectin-3  treatment  group  compared  with
vehicle  (P  <  0.01).
An  experimental  study  by  de  Boer  et  al.  [7]  showed
that  an  early  increase  in  galectin-3  expression  iden-
tiﬁed  failure-prone  hypertrophied  hearts.  Galectin-3,  a
macrophage-derived  mediator,  induces  cardiac  ﬁbroblast
proliferation,  collagen  deposition  and  ventricular  dysfunc-
tion.  This  implies  that  HF  therapy  aimed  at  inﬂammatory
responses  may  need  to  be  targeted  at  the  early  stages  of
HF  and  probably  needs  to  antagonize  multiple  inﬂamma-
tory  mediators,  including  galectin-3.  In  the  same  way,  in
myocardial  biopsies  of  aortic  stenosis  patients  undergoing
aortic  valve  replacement  [5],  myocardial  galectin-3  expres-
sion  was  increased  in  patients  with  a  depressed  ejection
fraction  compared  with  in  those  with  a  compensated  form
of  cardiac  hypertrophy  (7.08  ±  1.17  vs  4.60  ±  0.51;  P  <  0.05).
Measuring range and variability
The  galectin-3  measuring  range  is  1.4—94.8  ng/mL  for
clinical  specimens  [8].  Galectin-3  results  were  equivalent
when  measured  in  serum  or  ethylenediaminetetra-acetic
acid  (EDTA)  plasma.  The  90th,  95th  and  97.5th  percentiles
of  the  normal  reference  interval  were  17.6,  20.3  and
22.1  ng/mL,  respectively.  Imprecision  studies  demonstrated
that  the  total  coefﬁcient  of  variation  was  <  10%  at  a  low
concentration  of  6  ng/mL,  7%  near  the  mid-level  concen-
tration  of  21  ng/mL  and  15%  at  the  high  concentration  of
70  ng/mL.  The  limit  of  blank  was  0.86  ng/mL,  the  limit
of  detection  was  1.13  ng/mL  and  the  limit  of  quantiﬁ-
cation  was  0.96  ng/mL.  The  linear  measurement  range
was  0.96—130  ng/mL  and  there  was  no  high-dose  hook  at
concentrations  up  to  500  ng/mL.  Samples  can  be  stored
for  up  to  15  days  at  either  22—28 ◦C  or  2—8 ◦C  before
analysis;  measurements  are  stable  after  storage  at  −  20 ◦C
or  −70 ◦C  for  at  least  6  months  and  through  six  freeze-thaw
cycles.  No  cross-reactivity  with  nine  compounds  structurally
related  to  galectin-3  and  no  interference  from  22  common
medications,  icterus  or  lipaemia  were  found.  Haemolysis
is  known  to  interfere  with  the  measurement  of  galectin-3.
The  presence  of  human  anti-mouse  antibodies  or  rheuma-
toid  factor  may  interfere  with  the  galectin-3  assay,  which
could  cause  falsely  elevated  results.  Galectin-3  results
should  be  interpreted  with  caution  in  patients  with  a
history  of  therapeutic  use  of  murine  monoclonal  antibodies
(immunoglobulin  G)  or  their  fragments,  or  who  have  known
autoimmune  disorders.  Specimens  with  high  concentrations
of  gamma  globulin  (≥  2.5  g/dL)  may  have  false  elevation
of  results.  Galectin-3  results  from  patients  with  diseases
associated  with  hyperglobulinaemia,  such  as  multiple
myeloma,  should  be  interpreted  with  caution.
A  laboratory  sample  analysis  of  1092  healthy  volun-
teers  aged  ≥  55  years  from  the  Biolmage  cardiovascular
risk  study  showed  that  the  central  95%  normal  reference
interval  of  galectin-3  measured  by  the  galectin-3  assay  was
3.8—21.0  ng/mL;  galectin-3  was  detectable  in  the  plasma  of
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ll  healthy  individuals  and  exhibited  a  normal  distribution
8].
ssociated factors
hese  factors  are  usually  markers  associated  with  myocar-
ial  ﬁbrosis.  Indeed,  in  the  PREVEND  study,  galectin-3
oncentrations  were  measured  in  7968  individuals  from
he  general  population  [9]. Galectin-3  concentrations  were
lightly  higher  in  women  and  increased  from  age  30  years
o  75  years  by  approximately  1.5  ng/mL.  Signiﬁcant  positive
ssociations  were  found  with  age,  sex,  diabetes,  hyper-
ension,  hypercholesterolaemia,  body  mass  index,  renal
unction  (P  <  0.001  for  all)  and  smoking  (P  <  0.002)  [10].  How-
ver,  this  relationship  was  not  conﬁrmed  by  Shah  et  al.
11]  in  a  decompensated  HF  cohort  (did  not  differ  accord-
ng  to  sex  [P  =  0.92],  ethnicity  [P  =  0.48],  diabetic  status
P  =  0.58]  or  ischaemic  cause  [P  =  0.24]).  There  is  <  0.5%
ross-reactivity  with  other  galectin  isoforms  (galectin  1,  2,
,  7,  8,  9  and  12)  and  collagen  (I  and  III).  The  galectin-
 assay  can  be  used  to  measure  galectin-3  concentrations
n  both  serum  and  EDTA  plasma  samples.  In the  DEAL-
F  study  [12], galectin-3  concentrations  were  associated
ith  age  (r  =  0.318;  P  =  0.001);  younger  patients  had  lower
oncentrations.  Galectin-3  was  also  associated  with  renal
ysfunction  (glomerular  ﬁltration  rate  [GFR])  (r  =  —0.619;
 =  0.001);  higher  concentrations  were  found  in  patients  with
evere  renal  dysfunction  (GFR  <  30  mL/min).  Finally,  a  bor-
erline  statistically  signiﬁcant  association  was  found  with
ody  mass  index  (r  =  —0.154;  P  =  0.022).
linical studies
creening assessment
he  PREVEND  study  [9]  showed  that  the  highest  quintile  of
alectin-3  (median  15.6  ng/mL)  had  a  15%  10-year  mortality
ate  compared  with  a  5%  rate  for  those  in  the  lowest  quartile
median  7.7  ng/mL).
Galectin-3  concentrations  were  measured  in  3353  par-
icipants  in  the  Framingham  Offspring  Cohort  [10]  (mean
ge  59  years;  53%  women).  The  relationship  between
alectin-3  and  incident  HF  was  assessed  using  propor-
ional  hazards  regression.  Galectin-3  was  associated  with
ncreased  left  ventricular  mass  in  age-  and  sex-adjusted
nalyses  (P  =  0.001);  this  association  was  attenuated  in  mul-
ivariable  analyses  (P  =  0.06).  A  total  of  166  participants
eveloped  incident  HF  and  468  died  during  a  mean  follow-
p  period  of  11.2  years.  Galectin-3  was  associated  with  risk
f  incident  HF  (hazard  ratio  [HR]  1.28  per  1  SD  increase
n  log  galectin-3,  95%  conﬁdence  interval  [CI]  1.14—1.43;
 <  0.0001)  and  remained  signiﬁcant  after  adjustment  for
linical  variables  and  B-type  natriuretic  peptide  (BNP)  (HR
.23,  95%  CI  1.04—1.47;  P  =  0.02).  Galectin-3  was  also  associ-
ted  with  risk  of  all-cause  mortality  (multivariable-adjusted
R  1.15,  95%  CI  1.04—1.28;  P  =  0.01).  The  addition  of
alectin-3  to  clinical  factors  resulted  in  negligible  changes
o  the  C-statistic  and  minor  improvements  in  the  net  reclas-
iﬁcation  index.
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In  the  PROVE  IT-TIMI  22  study  [13],  100  patients  who
eveloped  HF  after  acute  coronary  syndrome  had  a  higher
aseline  galectin-3  concentration  (median  16.7  ng/L  [25th,
5th  percentile  14.0,  20.6]  vs  14.6  ng/L  [12.0,  17.6];
 =  0.004).
Patients  with  a  baseline  galectin-3  concentration  above
he  median  had  an  odds  ratio  (OR)  of  2.1  (95%  CI  1.2—3.6)
or  developing  HF  (P  =  0.010).  Galectin-3  showed  a  graded
elationship  with  risk  of  HF.  Cases  were  more  likely
o  have  hypertension,  diabetes,  prior  myocardial  infarc-
ion  and  prior  HF;  after  adjustment  for  these  factors,
his  graded  relationship  with  galectin-3  quartile  and  HF
emained  signiﬁcant  (adjusted  OR  1.4,  95%  CI  1.1—1.9;
 =  0.020).
cute heart failure assessment
ue  to  its  physiopathology,  there  is  no  clear  proof  of  the
ffectiveness  of  galectin-3  for  the  diagnosis  of  HF;  in  most
ases,  natriuretic  peptides  and  echocardiography  demon-
trated  high  accuracy.
However,  the  prognostic  power  of  galectin-3  has  under-
one  more  assessment.  The  PRIDE  study  for  assessment  of
cute  HF  was  a  multicentre  study  that  enrolled  599  con-
ecutive  patients  with  acute  or  decompensated  HF  and
roved  the  key  value  of  measuring  N-terminal  prohor-
one  of  BNP  (NT-proBNP)  to  help  clinicians  to  diagnose
F  [14].  The  PRIDE  study  population  was  drawn  from  con-
enting  patients  aged  >  21  years  who  presented  to  the
mergency  department.  Exclusion  criteria  for  the  study
ere  severe  renal  insufﬁciency  (serum  creatinine  concen-
ration  >  2.5  mg/dL,  dyspnoea  after  chest  trauma,  dyspnoea
econdary  to  severe  coronary  ischaemia  that  was  identiﬁed
s  >  0.1  mV  ST-segment  elevation  or  ST-segment  depression
n  a  12-lead  electrocardiogram  if  performed  at  presenta-
ion),  >  2-hour  delay  after  urgent  intravenous  loop  diuretic
dministration  (above  any  baseline  maintenance  dose)  and
nblinded  measurement  of  natriuretic  peptide  concentra-
ion.  Patients  who  developed  HF  had  a  higher  baseline
alectin-3  concentration  (median  16.7  g/L  [25th,  75th  per-
entile  14.0,  20.6]  vs  14.6  g/L  [12.0,  17.6];  P  =  0.004).
atients  with  a  baseline  galectin-3  concentration  above  the
edian  had  an  OR  of  2.1  (95%  CI  1.2—3.6)  for  develop-
ng  HF  (P  =  0.010).  Galectin-3  showed  a  graded  relationship
ith  risk  of  HF.  Cases  were  more  likely  to  have  hyperten-
ion,  diabetes,  prior  myocardial  infarction  and  prior  HF;
fter  adjustment  for  these  factors,  this  graded  relation-
hip  with  galectin-3  quartile  and  HF  remained  signiﬁcant
adjusted  OR  1.4,  95%  CI  1.1—1.9;  P  =  0.020).  Galectin-3
edians  and  interquartile  ranges  were  9.2  (7.4—12.1)  in
F  patients  and  6.9  (5.2—8.7)  in  non-HF  patients.  Com-
ared  with  NT-proBNP  and  all  clinical  data  available  in
hose  studies,  the  elevated  concentration  of  galectin-3
as  best  independent  predictor  of  60-day  mortality  (OR
0.3;  P  <  0.01)  and  60-day  death/recurrent  HF  (OR  14.3;
 <  0.001).
Shah  et  al.  [11]  evaluated  115  consecutive  patients  with
cute  dyspnoea  and  found  that  dyspnoeic  patients  with  HF
nd  galectin-3  concentrations  higher  than  the  median  value
f  15.0  (11.1—19.7)  had  a  63%  4-year  mortality  rate;  by
omparison,  patients  with  concentrations  lower  than  11.0
9.1—14.4)  had  a  37%  mortality  rate  (P  =  0.003).
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hronic heart failure assessment
alectin-3  concentration  was  measured  by  de  Boer  et  al.
15]  in  592  participants  hospitalized  with  HF  from  the  COACH
isease  management  trial.  Concentrations  of  galectin-3
ere  measured  prior  to  discharge  from  the  hospital  and
gain  at  approximately  6-month  follow-up.  Although  con-
entrations  were  stable  over  this  period,  the  baseline
oncentration  and  a  100%  increase  in  galectin-3  from  base-
ine  were  independent  predictors  of  HF  rehospitalization
nd  death  after  adjustment  for  age,  sex  and  natriuretic
eptide  concentrations:  adjusted  HRs  of  3.34  (95%  CI
.23—5.01;  P  <  0.001,  baseline  fourth  quartile)  and  1.77  (95%
I  1.42—2.20;  P  <  0.001  doubling  from  baseline),  respec-
ively.  A  doubling  of  galectin-3  concentration  over  6  months
as  associated  with  an  HR  of  1.97  (1.62—2.42)  for  the  pri-
ary  outcome  (P  = 0.001).  After  correction  for  age,  sex,  BNP,
stimated  GFR  and  diabetes,  the  HR  was  1.38  (1.07—1.78;
 =  0.015).  Galectin-3  concentrations  were  correlated  with
igher  interleukin-6  and  C-reactive  protein  concentrations
P  =  0.002).  The  predictive  value  of  galectin-3  was  stronger
n  patients  with  preserved  LVEF  (n  =  114)  compared  with
n  patients  with  reduced  LVEF  (P  =  0.001).  Galectin-3  is
n  independent  marker  for  outcome  in  HF  and  appears
o  be  particularly  useful  in  HF  patients  with  preserved
VEF.  Considering  HF  therapy,  plasma  galectin-3  concen-
rations  at  admission  were  lower  in  patients  receiving
eta-blockers  (13.4  ng/mL,  interquartile  range  11.9—16.3  vs
4.9  ng/mL,  interquartile  range  12.6—17.6;  P  =  0.024)  and
pironolactone  (13.1  ng/mL,  interquartile  range  11.0—15.3
s  14.3  ng/mL,  interquartile  range  12.3—17.2;  P  =  0.043)
omparing  with  in  untreated  patients.  In  an  another
dvanced  decompensated  HF  cohort  [15],  there  was  no
elationship  between  galectin-3  and  echocardiographic  or
aemodynamic  indexes,  but  higher  galectin-3  concentra-
ion  was  associated  with  poor  renal  function  (estimated
FR,  r  =  —0.24,  P  =  0.007;  cystatin  C,  r  =  0.38,  P  <  0.0001)  and
redicted  all-cause  mortality  (HR  1.86,  95%  CI  1.36—2.54;
 <  0.001).
In  data  from  DEAL-HF  [12], a  randomized  study  that
nrolled  232  patients  with  chronic  HF,  114  patients  (49%)
ad  galectin-3  plasma  concentrations  above  the  upper  limit
f  the  normal  cut-off  value  of  17.7  ng/mL.  For  all  study  sub-
ects,  the  mean  concentration  of  galectin-3  across  quartiles
as  18.6  ±  7.8  ng/mL.  There  was  no  signiﬁcant  correlation
etween  galectin-3  concentration  and  LVEF  or  aetiology
f  HF.  Globally,  the  galectin-3  concentration  was  associ-
ted  with  an  increased  risk  of  mortality  (HR  1.24,  95%  CI
.03—1.50;  P  =  0.26).
The  galectin-3  concentration  in  ambulatory  patients  with
hronic  HF  and  systolic  dysfunction  was  evaluated  in  the  HF-
CTION  study  [16].  Galectin-3  was  assessed  at  baseline  in  a
ohort  of  895  subjects  with  stored  plasma  samples  available.
he  association  between  galectin-3  and  clinical  outcomes
as  assessed  using  a  series  of  Cox  proportional  hazards
odels.  Higher  galectin-3  concentrations  were  associated
ith  other  measures  of  HF  severity,  including  higher  New
ork  Heart  Association  (NYHA)  class,  lower  systolic  blood
ressure,  higher  creatinine,  higher  NT-proBNP  and  lower
aximal  oxygen  consumption.  In  unadjusted  analysis,  there
as  a  signiﬁcant  association  between  elevated  galectin-3
oncentrations  and  hospitalization-free  survival  (unadjusted
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HR  1.14  per  3  ng/mL  increase  in  galectin-3;  P  =  0.0001).  In
multivariable  modelling,  the  prognostic  impact  of  galectin-3
was  signiﬁcantly  attenuated  by  the  inclusion  of  other  known
predictors.
Galectin-3  is  elevated  in  ambulatory  HF  patients  and  is
associated  with  poor  functional  capacity  and  other  known
measures  of  HF  severity.  In  univariate  analysis,  galectin-
3  was  signiﬁcantly  predictive  of  long-term  outcomes,  but
this  association  did  not  persist  after  adjustment  for  other
predictors.
Tang  et  al.  [17],  who  evaluated  chronic  HF  and  advanced
decompensated  HF  in  178  patients,  found  that  higher
galectin-3  concentration  was  associated  with  poor  renal
function  (estimated  GFR,  r  =  —0.24,  P  <  0.007;  cystatin  C,
r  =  0.38,  P  <  0.0001)  and  predicted  all-cause  mortality  (HR
1.86,  95%  CI  1.36—2.54;  P  <  0.001).
In  a  clinical  study  by  Lin  et  al.  [18],  a  total  of  106
patients  were  enrolled  (83  men).  The  mean  age  was  61  ±  16
years,  mean  LVEF  was  35  ±  9%  and  mean  NYHA  functional
class  was  2.  Log  galectin-3  was  signiﬁcantly  correlated
with  log  N-terminal  propeptide  of  type  III  procollagen  (PII-
INP)  (P  =  0.006),  log  tissue  inhibitor  of  metalloproteinase-1
(TIMP-1)  (P  =  0.025),  log  matrix  metalloproteinase-2  (MMP-
2)  (P  =  0.016)  and  NYHA  functional  class  (P  =  0.034),  but  not
age,  sex  or  LVEF.  After  adjusting  for  age,  sex,  smoking  status
and  LVEF,  the  relationship  between  galectin-3  and  extracel-
lular  matrix  turnover  biomarkers  (including  PIIINP,  TIMP  and
MMP-2)  remained  signiﬁcant.  After  adjusting  for  age,  sex,
smoking  status  and  NYHA  functional  class,  the  relationship
between  galectin-3  and  PIIINP  or  MMP-2  remained  signiﬁ-
cant.
An  interesting  study  by  Milting  et  al.  [19]  described
the  kinetics  of  galectin-3  in  55  patients  with  end-stage
HF  with  the  need  for  mechanical  circulatory  support.  This
study  determined  that  ﬁbrosis-related  biomarkers,  includ-
ing  galectin-3,  were  increased  compared  with  controls;
that  where  there  was  no  reduction  of  galectin-3  concentra-
tion  by  mechanical  circulatory  support  only  loading-related
biomarker  BNP  was  reduced;  and  that  patients  who  did
not  survive  on  mechanical  circulatory  support,  had  a  higher
baseline  galectin-3  concentration.
Galectin-3 and natriuretic biomarkers of  heart
failure
Shah  et  al.  [11],  in  an  evaluation  of  acute  HF,  found
that  combining  plasma  galectin-3  and  BNP  concentrations
increased  prognostic  value  over  either  biomarker  alone
(receiver  operating  characteristic  analysis,  P  =  0.05).  In  the
DEAL-HF  study  [12],  galectin-3  concentrations  were  also
increased  in  patients  with  higher  NT-proBNP  concentrations
(r  =  0.265;  P  <  0.001).  In  the  PROVE  IT-TIMI  22  study  [15,16],
when  BNP  was  added  to  the  model  of  HF  development,
the  relationship  between  galectin-3  and  HF  was  attenuated
(adjusted  OR  1.3,  95%  CI  0.96—1.9;  P  =  0.08).
In  the  PROVE  IT-TIMI  22  study  [13],  galectin-3  did  not  sig-
niﬁcantly  correlate  with  BNP  (Spearman’s  P  =  0.13;  P  =  0.08).
When  both  BNP  and  galectin-3  were  included  in  the  multi-
variable  model,  however,  the  graded  relationship  between
galectin-3  and  HF  was  attenuated  (adjusted  OR  1.3,  95%  CI
0.96—1.9;  P  =  0.08).  When  patients  were  stratiﬁed  by  both
i
c
p
r545
alectin-3  at  the  median  and  BNP  at  the  cut-off  point  of
0  pg/mL,  patients  with  increased  galectin-3  and  BNP  had
he  highest  odds  of  HF:  OR  4.7  (95%  CI  1.7—13.0;  P =  0.002)
or  high  BNP/high  galectin-3  compared  with  the  referent  of
ow  BNP/low  galectin-3.
However,  in  multivariable  modelling  and  univariate  anal-
sis  in  the  HF-ACTION  study  [16], galectin-3  was  not  a
igniﬁcant  predictor  of  cardiovascular  death  or  cardiovascu-
ar  hospitalization  after  the  further  addition  of  NT-proBNP
HR  0.97;  P  =  0.36).  For  all-cause  mortality,  galectin-3  was
ot  signiﬁcant  after  further  adjustment  for  NT-proBNP
adjusted  HR  1.06;  P  =  0.30).
alectin-3—a promising target in HF therapy?
he  direct  inhibition  of  galectin-3  is  possible  by  N-acetyl-
eryl-aspartyl-lysyl-proline  (Ac-SDKP),  a  naturally  occurring
etrapeptide  that  prevents  and  reverses  inﬂammation  and
ollagen  deposition  in  the  heart  in  hypertension  and  HF  after
yocardial  infarction.  In  the  present  study,  we  hypothesize
hat  Ac-SDKP  prevents  galectin-3-induced  cardiac  inﬂamma-
ion,  remodelling  and  dysfunction  and  that  these  effects  are
ediated  by  the  transforming  growth  factor  signalling  path-
ay.  Ac-SDKP  prevents  cardiac  remodelling  and  dysfunction
nduced  by  galectin-3,  a  mammalian  adhesion/growth-
egulatory  lectin  [6,20].
The  impact  of  statins  on  galectin-3  concentration  was
hown  in  the  CORONA  study  [21]:  1492  patients  aged  >  60
ears  were  included,  with  chronic  HF  of  ischaemic  cause,
n  NYHA  class  II—IV  and  with  LVEF  ≤  40%  (≤  35%  if  NYHA
I).  The  patients  were  randomly  assigned  to  rosuvastatin
0  mg/day  or  placebo.  Galectin-3  was  measured  in  plasma.
he  primary  outcome  was  cardiovascular  death,  myocardial
nfarction  or  stroke.  Of  1492  patients,  411  had  a  primary
vent  during  a  median  follow-up  of  32.8  months.  There  was
n  interaction  between  baseline  galectin-3  concentration
nd  rosuvastatin  on  the  primary  endpoint  (P  value  for  inter-
ction  =  0.036).  Among  patients  with  below  median  plasma
oncentrations  of  galectin-3  (≤  19.0  ng/mL),  those  assigned
o  rosuvastatin  had  a  lower  primary  event  rate  (HR  0.65,
5%  CI  0.46—0.92;  P  =  0.014),  lower  total  mortality  (HR  0.70,
5%  CI  0.50—0.98;  P  = 0.038)  and  a  lower  event  rate  for  all-
ause  mortality  and  HF  hospitalizations  (HR  0.72,  95%  CI
.54—0.98;  P  =  0.017)  compared  with  placebo,  but  no  ben-
ﬁt  was  observed  in  patients  with  higher  concentrations  of
alectin-3.  The  combination  of  concurrently  low  concentra-
ions  of  galectin-3  and  NT-proBNP  (102.7  pmol/L)  identiﬁed
atients  with  a  large  beneﬁt  with  rosuvastatin  (HR  0.33,  95%
I  0.16—0.67;  P  =  0.002)  in  the  CORONA  study  [21].  Patients
ith  systolic  HF  of  ischaemic  aetiology  who  have  galectin-3
oncentrations  ≤  19.0  ng/mL  may  beneﬁt  from  rosuvastatin
reatment.  However,  the  data  from  this  post  hoc  analysis
hould  be  interpreted  with  caution  as  the  overall  results  of
he  CORONA  study  did  not  show  a  signiﬁcant  effect  on  the
rimary  endpoint.
According  to  data  from  clinical  studies,  measurement
f  galectin-3  concentration  can  be  integrated  into  the
anagement  of  patients  with  chronic  HF  [22,23].  Forndividuals  with  a  galectin-3  concentration  ≤  17.8  ng/mL,
ontinuation  of  usual  care  is  suggested,  with  periodic  out-
atient  follow-up  visits;  for  those  in  the  17.9—25.9  ng/mL
ange  which  constitutes  moderate  risk,  more  intensiﬁed
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[23] McCullough PA, Philbin EF, Spertus JA, et al. Conﬁrmation of46  
are  management  is  suggested,  with  possibly  more  frequent
isits,  medication  monitoring  and  adjustment.  Finally,
or  those  with  concentrations  >  25.9  ng/mL  or  a  doubling
f  galectin-3,  there  is  a  very  high  risk  of  hospitalization
28%)  and  death  over  18  months  (43%);  accordingly,  they
hould  receive  particular  attention,  with  optimal  care  and
dvanced  management  strategies.
onclusions
alectin-3  is  expressed  in  various  tissues  and  cell  types
nd  is  involved  in  many  biological  processes,  such  as  cell-
ell  and  cell-extracellular  matrix  adhesion,  cell  growth  and
ifferentiation,  the  cell  cycle,  signalling,  apoptosis  and
ngiogenesis.  Consequently,  galectin-3  is  involved  in  the  reg-
lation  of  development  and  immune  reactions.
An  increased  concentration  of  galectin-3  was  found  in
he  patients  with  chronic  HF,  regardless  of  aetiology  and
F  typology  (with  preserved  or  reduced  ejection  fraction),
nd  in  acute  HF,  hypertrophic  hearts  and  aortic  stenosis
ith  systolic  dysfunction.  Galectin-3  concentration  is  prob-
bly  correlated  with  age  and  renal  failure,  but  not  with
chocardiographic  and  haemodynamic  HF  data.  The  speciﬁc
alectin-3  pathway,  underlining  cardiac  ﬁbrosis,  seems  very
romising  for  high-risk  patient  identiﬁcation.  Galectin-3  has
 very  high  predictive  value  in  terms  of  short-  and  long-
erm  prognosis  and  an  additive  value  to  natriuretic  peptide
easurement.  Complementary  prospective  studies  are  still
eeded  to  conﬁrm  its  prognostic  value  and  to  determine
he  target  population  for  combined  biomarker  analysis  and,
aybe  in  the  future,  for  using  galectin-3  as  a  target  for  HF
herapy.
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